Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation

Arquivos Brasileiros de Cardiologia

Volumn 98, Issue 6, 2012, Pages 528-536

  Guérios, Ênio Eduardo ^a,b   Schmid, Michael ^a   Gloekler, Steffen ^a   Khattab, Ahmed A ^a   Wenaweser, Peter M ^a   Windecker, Stephan ^a   Meier, Bernhard ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b Centro de Cardiopatias Congênitas e Estruturais do Paraná ^*  (Brazil)

Author keywords

Arrhythmias cardiac complications; Atrial appendage; Atrial fibrillation; Prostheses and implants

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL EMBOLISM; CONTROLLED STUDY; DEATH; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM APPENDAGE; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM APPENDAGE CLOSURE; HEART TAMPONADE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON VALVULAR ATRIAL FIBRILLATION; PERICARDIAL EFFUSION; PERICARDIOCENTESIS; SEPTAL OCCLUDER; THROMBOGENESIS; TRANSIENT ISCHEMIC ATTACK;

AGED; AGED, 80 AND OVER; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; CARDIAC CATHETERIZATION; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSTHESIS DESIGN; RISK FACTORS; SEPTAL OCCLUDER DEVICE; TREATMENT OUTCOME;

EID: 84866093739     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2012005000044     Document Type: Article

References (38)

1. Roger VL, Go AS, Lloyd-Jones DM, Adams RJ, Berry JD, Brown TM, et al. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
2. Singh IM, Holmes Jr DR. Left atrial appendage closure. Curr Cardiol Rep. 2010;12(5):413-21.
3. Fuller CJ, Reisman M. Stroke prevention in atrial fibrillation: atrial appendage closure. Curr Cardiol Rep. 2011;13(2):159-66.
4. Camm AJ, Kirchhof P, Lip GYH, Schoeten U, Savelieva I, Ernst S, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369-429.
5. Ederhy S, Dufaitre G, Boyer-Chatenet L, Boyer-Chatenet, Meuleman C, Di Angelantonio E, et al. Should all patients with non-valvular atrial fibrillation be anticoagulated? Int J Cardiol. 2010;143(1):8-15.
6. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg. 1996;61(2):755-9.
7. Healey JS, Crystal E, Lamy A, Teoh K, Semelhago L, Hohnloser SH, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. Am Heart J. 2005;150(2):288-93.
8. Park JW, Bethencourt A, Sievert H, Santoro G, Meier B, Walsh K, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv. 2011;77(5):700-6.
9. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857-67.
10. White HD, Gruber M, Feyzi J, Kaatz S, Tse HF, Husted S, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-45.
11. Mega JL. A new era for anticoagulation in atrial fibrillation. N Engl J Med. 2011;365(11):1052-4.
12. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med. 2007;167(13):1414-9.
13. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgreen J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139-51
14. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-91.
15. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrilation. N Engl J Med. 2011;365(10):981-92.
16. Douketis JD. Dabigatran as anticoagulant therapy for atrial fibrillation. Which patients should receive it, which patients may not need it, and other practical aspects of patient management. Pol Arch Med Wewn. 2011;121(3):73-80.
17. Legrand M, Mateo J, Aribaud A, Ginisty S, Eftekhari P, Huy PT, et al. The use of dabigatran in elderly patients. Arch Intern Med. 2011;171(14):1285-6.
18. Jacobs JM, Stessman J. New anticoagulants among elderly patients is caution necessary?: Comment on «The use of dabigatran in elderly patients» Arch Intern Med. 2011;171:1287-8.
19. Gage BF. Can we rely on RE-LY? N Engl J Med. 2009;361(12):1200-2.
20. Khattab AA, Meier B. Transcatheter left atrial appendage exclusion, gold or fool's gold? Eur Heart J Suppl. 2010;12 (Suppl. E):E35-E40.
21. Johnson WD, Ganjoo AK, Stone CD Srivyas RC, Howard M. The left atrial appendage: our most lethal human attachment! Surgical implications. Eur J Cardiothorac Surg. 2000;17(6):718-22.
22. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Comitee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Circulation. 2008;118(15):e523-661.
23. Dawson AG, Asopa S, Dunning J. Should patients undergoing cardiac surgery with atrial fibrillation have left atrial appendage exclusion? Interact Cardiovasc Thorac Surg. 2010;10(2):306-11.
24. Meier B, Palacios I, Windecker S, Rotter M, Cao QL, Keane D, et al. Transcatheter left atrial appendage occlusion with Amplatzer devices to obviate anticoagulation in patients with atrial fibrillation. Catheter Cardiovasc Interv. 2003;60(3):417-22.
25. Sievert H, Lesh MD, Trepels T, Omran H, Bartorelli A, Della Bella P, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation. 2002;105(16):1887-9.
26. Ostermayer SH, Reisman M, Kramer PH, Mattheu's RV, Gray WA, Block PC, et al. Percutaneous left atrial appendage transcatheter occlusion (PLAATO system) to prevent stroke in high-risk patients with non-rheumatic atrial fibrillation: results from the international multi-center feasibility trials. J Am Coll Cardiol. 2005;46(1):9-14.
27. Block PC, Burstein S, Casale PN, Kramer PH, Teirstein P, Williams DO, et al. Percutaneous left atrial appendage occlusion for patients in atrial fibrillation suboptimal for warfarin therapy: 5-year results of the PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study. J Am Coll Cardiol. 2009;2(7):594-600.
28. Gorodnitskiy A, Lucariello RJ, Aizer A, Coppola JT. A novel approach to left atrial appendage occlusion: the Watchman device. Cardiol Rev. 2010;18(5):230-3.
29. Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009;374(9689):534-42.
30. Reddy VY, Holmes DR, Doshi SK, Neuzil P, Kar S. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients With AF (PROTECTAF) Clinical Trial and the Continued Access Registry. Circulation. 2011;123(4):417-24.
31. Armaganijan LV, Staico R, Pedra SF, Moreira DA, Braga SL, Feres F, et al. Experiência inicial com o novo Amplatzer Cardiac Plug para oclusão percutânea do apêndice atrial esquerdo. Rev Bras Cardiol Invas. 2011;19(1):14-23.
32. Bass JL. Transcatheter occlusion of the left atrial appendage - experimental testing of a new Amplatzer device. Catheter Cardiovasc Interv. 2010;76(2):181-5.
33. Meier B. Left atrial appendage closure: do we have one ear too many? Cardiac & Vascular Update 2010;3:12-4.
34. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864-70.
35. Olesen JB, Lip GY, Hansen ML, Tolostrup IS, Lindhardsen J, Selmer C, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ. 2011;342:d124.doi: 10.1136/bmj.d124
36. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess one-year risk of majorbleeding in atrial fibrillation patients: the Euro Heart Survey. Chest. 2010;138(5):1093-100.
37. Krumsdorf U, Ostermayer S, Billinger K, Trepels T, Zadan E, Horvath K, et al. Incidence and clinical course of thrombus formation on atrial septal defect and aptent foramen ovale closure devices in 1,000 consecutive patients. J Am Coll Cardiol. 2004;43(2):302-9.
38. Cruz-Gonzalez I, Moreiras JM, García E. Thrombus formation after left atrial appendage exclusion using an Amplatzer Cardiac Plug device. Catheter Cardiovasc Interv. 2011;78(6):970-3.